

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

**APPROVAL FOR CLINICAL TRIAL OF UBT251 INJECTION
ON INDICATION OF NON-ALCOHOLIC FATTY LIVER DISEASE**

This announcement is made by The United Laboratories International Holdings Limited (the “Company”) on a voluntary basis.

The board of directors (the “Board”) of the Company is pleased to announce that on 8 September 2023, the application for the clinical trial of class 1 innovative new drug UBT251 Injection self-developed by The United Bio-Technology (Hengqin) Co., Ltd., a wholly-owned subsidiary of the Company, on indication of non-alcoholic fatty liver disease (NAFLD) was approved by China National Medical Products Administration, with reference number of CXHL2300700.

UBT251 is a long-acting triple agonist of GLP-1 (glucagon-like peptide-1) /GIP (glucose-dependent insulinotropic polypeptide) /GCG (glucagon). As shown by the early human clinical trial results of drugs with the same type of targets, after a dosage period of more than 48 weeks, they can effectively reduce blood glucose and body weight, reduce liver fat and improve blood pressure and blood lipids, showing significant improvement in patients’ overall metabolism.

At present, the Company is the first enterprise in China and the second enterprise in the world to be approved for the clinical trials of a long-acting triple agonist of GLP-1/GIP/GCG prepared by chemical synthetic polypeptide. UBT251 Injection on indications of adult type 2 diabetes and overweight or obesity have been approved for clinical trial on 29 August 2023 and 1 September 2023 respectively.

In the future, the Company will continue to commit itself to the research and development of new products, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating more benefits for the Company and its shareholders.

By Order of the Board

The United Laboratories International Holdings Limited

Tsoi Hoi Shan

Chairman

Hong Kong, 8 September 2023

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.